Filter by Document Type
MO SB 26 Comment Letter (2023)
Comment letter addressing white bagging, biosimiliars, and 340b provisions in MO SB 26.
Biosimilars Competition Reduce Costs One Pager (2021)
Includes a chart that shows how after Biosimilars launch, reference biologics’ list price increases stop and net costs fall.
The Critical Path Forward: Rx Policies to Reduce Patient Costs, Improve Access (2021)
One-pager explaining the value of generic competition in the market to reduce costs and increase access.
PCMA Oppose CT SB 197 (2018)
This PCMA comment letter was submitted to the CT Joint Committee on General Law regarding SB197 which deals with interchangeable biologics. The bill would allow
